Published in:
01-11-2013 | Original Article—Liver, Pancreas, and Biliary Tract
Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstruction
Authors:
Yousuke Nakai, Hiroyuki Isayama, Tsuyoshi Mukai, Takao Itoi, Iruru Maetani, Hiroshi Kawakami, Ichiro Yasuda, Hiroyuki Maguchi, Shomei Ryozawa, Keiji Hanada, Osamu Hasebe, Kei Ito, Hiorofumi Kawamoto, Hitoshi Mochizuki, Yoshinori Igarashi, Atsushi Irisawa, Tamito Sasaki, Osamu Togawa, Taro Hara, Hideki Kamada, Nobuo Toda, Tsuyoshi Hamada, Hirofumi Kogure
Published in:
Journal of Gastroenterology
|
Issue 11/2013
Login to get access
Abstract
Background
In patients with unresectable malignant biliary obstruction (MBO), anticancer treatment is often administered. The impact of anticancer treatment on recurrent biliary obstruction in covered self-expandable metallic stents (SEMS) has not been fully elucidated.
Methods
Data on 279 patients enrolled in a multicenter prospective cohort study of two different covered SEMS for distal MBO, WATCH study (141 partially covered WallFlex stents and 138 partially covered Wallstents) were retrospectively analyzed. The rates and causes of recurrent biliary obstruction (stent occlusion or migration) were compared between anticancer treatment group (n = 173) and best supportive care alone (BSC) group (n = 106). Cumulative time and prognostic factors for recurrent biliary obstruction were analyzed, using a proportional hazards model with death without recurrent biliary obstruction as a competing risk.
Results
The overall rate (43 vs. 25 %, P = 0.002) and the cumulative incidence (16.1 vs. 8.2, 27.9 vs. 18.9 and 44.1 vs. 26.6 % at 3, 6 and 12 months, P = 0.030 by Gray’s test) of recurrent biliary obstruction were significantly higher in anticancer treatment group compared with BSC group. The multivariate analysis revealed anticancer treatment [subdistribution hazard ratio (SHR) 1.93, P = 0.007) as well as the use of a partially covered WallFlex stent (SHR 0.65, P = 0.049) as prognostic factors.
Conclusions
Anticancer treatment was a risk factor for recurrent biliary obstruction in covered SEMS for distal MBO. The superiority of a partially covered WallFlex stent was again confirmed in this competing risk analysis; UMIN-CTR: UMIN000002293.